TABLE 1.
Serotype(s) | Age group (yr) | 1999
|
2002
|
Change in rate | P valuec | ||
---|---|---|---|---|---|---|---|
No. of cases | Rateb | No. of cases | Rate | ||||
All | <5 | 1,167 | 96.36 | 308 | 24.05 | −72.31 | <0.001 |
≥5 | 3,141 | 19.08 | 2,418 | 13.72 | −5.36 | <0.001 | |
All | 4,308 | 24.37 | 2,726 | 14.42 | −10.05 | <0.001 | |
PCV7 serogroups except 19A | <5 | 1,064 | 87.85 | 143 | 11.16 | −76.69 | <0.001 |
≥5 | 2,067 | 12.55 | 1,233 | 7.00 | −5.55 | <0.001 | |
All | 3,131 | 17.71 | 1,376 | 7.28 | −10.43 | <0.001 | |
Non-PCV7 serogroups plus 19A | <5 | 103 | 8.50 | 165 | 12.88 | +4.38 | <0.001 |
≥5 | 1,067 | 6.48 | 1,185 | 6.72 | +0.24 | 0.4 | |
All | 1,170 | 6.62 | 1,350 | 7.14 | +0.52 | 0.06 |
The surveillance areas included California (San Francisco only), Connecticut (state), Georgia (the 20-county Atlanta metro area), Maryland (the 7-county Baltimore II area), Minnesota (the 7-county Twin Cities area), New York (the 15-county Albany and Rochester areas), Oregon (the 3-county Portland area), and Tennessee (4 counties).
Number of cases per 100,000 individuals.
P values are for 1999 versus 2002.